evofem is a biotechnology company focusing on developing innovative reproductive health products for women in every global market. evofem develops and markets products that are woman-controlled, non-invasive and rapidly reversible. women need access to effective products that are well suited to their lifestyle and consistent with their core values. products include: amphora™ - a non-hormonal vaginal gel being investigated for contraceptive and microbicidal properties.
Company profile
Ticker
EVFM
Exchange
Website
CEO
Saundra Pelletier
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Neothetics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Evofem Biosciences Operations, Inc. • Evofem, Inc. ...
EVFM stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
28 Mar 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
27 Mar 24
8-K
Entry into a Material Definitive Agreement
6 Mar 24
8-K
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
1 Feb 24
8-K
Entry into a Material Definitive Agreement
31 Jan 24
8-K/A
Financial Statements and Exhibits
25 Jan 24
8-K
Entry into a Material Definitive Agreement
11 Jan 24
8-K
Entry into a Material Definitive Agreement
26 Dec 23
8-K
Entry into a Material Definitive Agreement
12 Dec 23
Transcripts
EVFM
Earnings call transcript
2022 Q2
5 Aug 22
EVFM
Earnings call transcript
2022 Q1
5 May 22
EVFM
Earnings call transcript
2021 Q4
4 Mar 22
EVFM
Earnings call transcript
2021 Q3
16 Nov 21
EVFM
Earnings call transcript
2021 Q2
12 Aug 21
EVFM
Earnings call transcript
2021 Q1
7 May 21
EVFM
Earnings call transcript
2020 Q4
5 Mar 21
EVFM
Earnings call transcript
2020 Q3
9 Nov 20
EVFM
Earnings call transcript
2020 Q3
9 Nov 20
EVFM
Earnings call transcript
2020 Q2
4 Aug 20
Latest ownership filings
SC 13G/A
CVI Investments, Inc.
14 Feb 24
4
Yan Zhang
12 Jan 24
4
Kim P. Kamdar
22 Dec 23
5
Justin J. File
8 May 23
4
SAUNDRA L PELLETIER
26 Apr 23
3
Yan Zhang
26 Apr 23
SC 13G/A
CVI Investments, Inc.
14 Feb 23
SC 13G/A
Cox Todd Stewart
10 Aug 22
3
Jenny C. Yip
8 Aug 22
SC 13G
Cox Todd Stewart
19 Jul 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 410.00 k | 410.00 k | 410.00 k | 410.00 k | 410.00 k | 410.00 k |
Cash burn (monthly) | 75.33 k | 786.00 k | (no burn) | (no burn) | 788.00 k | 1.28 mm |
Cash used (since last report) | 513.87 k | 5.36 mm | n/a | n/a | 5.38 mm | 8.71 mm |
Cash remaining | -103.87 k | -4.95 mm | n/a | n/a | -4.97 mm | -8.30 mm |
Runway (months of cash) | -1.4 | -6.3 | n/a | n/a | -6.3 | -6.5 |
Institutional ownership, Q2 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Jan 24 | Yan Zhang | Common Stock | Sell | Dispose S | No | No | 0.0385 | 104 | 4.00 | 0 |
21 Dec 23 | Kamdar Kim P. | Common Stock | Sell | Dispose S | No | No | 0.621 | 10 | 6.21 | 0 |
31 Dec 22 | Pelletier Saundra L | Common Stock | Sale back to company | Dispose D | No | No | 0 | 50,000 | 0.00 | 186,722 |
31 Dec 22 | File Justin J. | Common Stock | Sale back to company | Dispose D | No | No | 0 | 30,000 | 0.00 | 24,065 |
Press releases
Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO
18 Apr 24
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
27 Mar 24
Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal
20 Mar 24
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
7 Mar 24
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
1 Feb 24